People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, ...

"That's a big one," said Trump, as he was handed the WHO order to sign among dozens of others, in a signal of his ...

In a new white paper from Altmetric – ‘The changing landscape of journal performance measurement’ – learn how publication ...

While AI has revolutionised drug discovery and development in life sciences, its impact in commercialisation has been slower.

In Part 4 of our Life Sciences Industry Report, we turn our attention to advanced data analytics, wearable health devices, ...

As the race to deliver personalised engagement at scale gains pace, artificial intelligence (AI) has become a critical ...

In another inflection point for the psychedelic medicines category, Mind Medicine (MindMed) has claimed breakthrough status from the FDA for its LSD-based candidate MM120 as a treatment for anxiety.

Investors in TauRx Pharma have exercised warrants worth around $119 million, adding to the biotech's financial resources as it prepares regulatory filings for tau-targeting Alzheimer's drug ...

Artificial intelligence (AI) and omnichannel have come to seem mere buzzwords these days in the life sciences – everyone is talking about them, everyone wants to use them. But without knowledge ...

Shares in Scholar Rock have gone into overdrive after the biotech reported positive phase 3 results with apitegromab in patients with spinal muscular atrophy (SMA), setting up regulatory filings ...

A subsidiary of Sun Pharma has reached an agreement to buy the assets of Canada's Antibe Therapeutics, a developer of drugs ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity ...